Canaccord Genuity Maintains a Buy Rating on TSO3 Inc. J

By Ryan Adsit

In a latest note to investors, a research analyst has provided a rating update for the Healthcare company, TSO3 Inc. J (TSX: TOS). Today, analyst Neil Maruoka gave a Buy rating to TOS and set a C$2 price target.

According to TipRanks.com, Maruoka is ranked #581 out of 4830 analysts.

Read also: Idera Pharmaceuticals (IDRA) Shares Dive on Clinical Setback

TSO3 Inc. J has an analyst consensus of Moderate Buy, with a price target consensus of C$1.80.

Based on TSO3 Inc. J’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of C$5.71 million. In comparison, last year the company had a GAAP net loss of C$2.62 million.

TSO3, Inc. engages in the business of medical devices. Its activities include manufacturing, sale; research and development, licensing of sterilization processes, related consumable supplies, and accessories for medical devices that are sensitive to heat and moisture. It operates through the Canada and Worldwide; and United States geographical segments.

The company’s shares closed on Thursday at C$1.07.